Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
Rana R. McKay(University of California San Diego), M-E Taplin(Dana-Farber Cancer Institute), Kaitlyn Melnick(University of Florida), Lillian Werner(Dana-Farber Cancer Institute), Olga Voznesensky(Beth Israel Deaconess Medical Center), Katherine Zukotynski(Unknown), Xin Yuan(Shanghai University of Traditional Chinese Medicine), Philip W. Kantoff(Convergent Science (United States)), Steven P. Balk(Beth Israel Deaconess Medical Center), Jifeng Wu(Beth Israel Deaconess Medical Center), Zhiyong Jiang(Guangzhou Medical University), Bruce Montgomery(Fred Hutch Cancer Center), Stephen Smith(Dezful University of Medical Sciences)
Cited by 37
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k